Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
KNSA 
Kiniksa Pharmaceuticals Ltd (KNSA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/09/2025: KNSA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $38
1 Year Target Price $38
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.44% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/09/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.04B USD | Price to earnings Ratio - | 1Y Target Price 38 |
Price to earnings Ratio - | 1Y Target Price 38 | ||
Volume (30-day avg) 6 | Beta 0.05 | 52 Weeks Range 17.82 - 30.69 | Updated Date 07/8/2025 |
52 Weeks Range 17.82 - 30.69 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.52% | Operating Margin (TTM) 9.63% |
Management Effectiveness
Return on Assets (TTM) -1.77% | Return on Equity (TTM) -3.81% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1781113526 | Price to Sales(TTM) 4.24 |
Enterprise Value 1781113526 | Price to Sales(TTM) 4.24 | ||
Enterprise Value to Revenue 3.7 | Enterprise Value to EBITDA -44.93 | Shares Outstanding 42336200 | Shares Floating 36280435 |
Shares Outstanding 42336200 | Shares Floating 36280435 | ||
Percent Insiders 3.83 | Percent Institutions 96.01 |
Upturn AI SWOT
Kiniksa Pharmaceuticals Ltd
Company Overview
History and Background
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with debilitating diseases with unmet medical need. Founded in 2015.
Core Business Areas
- Immunology: Focuses on developing therapies for inflammatory and autoimmune diseases.
- Rare Diseases: Develops treatments for rare and often genetic disorders.
Leadership and Structure
The leadership team is headed by the CEO. The company has functional departments covering research, development, commercial, and administrative operations. Specific names and details would require accessing current public filings or their website.
Top Products and Market Share
Key Offerings
- Mavrilimumab (formerly known as MAV, now discontinued): An anti-GM-CSF receptor alpha monoclonal antibody. The program was terminated. Competing products include TNF inhibitors and other biologics targeting inflammatory pathways from companies like AbbVie, Amgen, and Novartis.
- Rilonacept (ARCALYST): Recombinant fusion protein that blocks IL-1. Used for cryopyrin-associated periodic syndromes (CAPS). It is now owned by Regeneron. Competitors include Ilaris (Novartis) which also targets IL-1.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. Innovation and patent protection are critical for success.
Positioning
Kiniksa focuses on niche markets within immunology and rare diseases. Their success depends on clinical trial outcomes and regulatory approvals.
Total Addressable Market (TAM)
The TAM for inflammatory and rare diseases is significant, estimated in the billions of dollars annually. Kiniksa's positioning depends on the specific indications they target and their ability to penetrate those markets.
Upturn SWOT Analysis
Strengths
- Focus on specific therapeutic areas
- Innovative pipeline (if applicable, details needed from current status)
- Experienced management team
Weaknesses
- Reliance on clinical trial success
- Competition from larger pharmaceutical companies
- Financial resources relative to larger companies
Opportunities
- Expanding into new indications
- Partnering with larger pharmaceutical companies
- Acquiring new technologies or assets
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from biosimilars or generics
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- ABBV
- AMGN
- NVS
Competitive Landscape
Kiniksa faces competition from larger, more established pharmaceutical companies with greater resources. Their competitive advantage lies in their focus on specific therapeutic areas and their innovative pipeline.
Growth Trajectory and Initiatives
Historical Growth: Historical growth depends on product approvals and commercial success. This would require a review of historical financial statements.
Future Projections: Future growth projections would depend on analyst estimates, which are based on pipeline potential and market opportunities.
Recent Initiatives: Recent initiatives would include any new clinical trials, regulatory filings, or partnerships.
Summary
Kiniksa Pharmaceuticals is a biopharmaceutical company focused on unmet medical needs and it is small in comparison to other bigger companies, which can be a strength and a weakness. It needs to be aware of its competitors and continue innovating to develop therapeutic medicines for debilitating diseases. Kiniksa Pharmaceuticals Ltd has not paid dividends to shareholders.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kiniksa Pharmaceuticals Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-05-24 | CEO & Chairman of the Board Mr. Sanj K. Patel | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 315 | Website https://www.kiniksa.com |
Full time employees 315 | Website https://www.kiniksa.com | ||
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.